CBChristopher J. Bakkenist

Christopher J. Bakkenist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher J. Bakkenist has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Handrick Beumer

    Johns Hopkins School of Medicine, Baltimore, Maryland

    9 shared publications
  • Frank P. Vendetti

    Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    7 shared publications
  • Serah Choi

    UPMC Medical Education Transitional Year Residency Program, University of Pittsburgh School of Medicine, Hillman Cancer Center, Research Pavilion, Pittsburgh, PA 15213, USA

    7 shared publications
  • Pinakin Pandya

    Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    6 shared publications
  • Jan H. Beumer

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh

    5 shared publications
  • Sandra Schamus-Haynes

    Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    5 shared publications

Latest Publications

  • Open Access

    Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC–MS/MS

    by Joshua J. Deppas, Reyna Jones, Robert A. Parise, Pinakin Pandya, Christopher J. Bakkenist, Jan H. Beumer

    Deoxyuridine (dUrd) is often misincorporated into genomic DNA in cancer patients receiving antimetabolite chemotherapy. This activates base excision repair and recruits ataxia telangiectasia‐mutated and Rad3‐related (ATR), which coordinates DNA repair with nucleotide metabolism by facilitating ribonucleotide reductase (RNR) activity. Ceralasertib (AZD6738) is the most clinically advanced ATR inhibitor (ATRi) and may abrogate this regulatory pathway and diminish RNR‐mediated deoxynucleotide triphosphate synthesis. To further understand ATRi‐induced dUrd misincorporation, we developed a highly sensitive LC–MS/MS method to quantitate: deoxyuridine, uridine, guanosine, adenosine, cytidine, thymidine, deoxyguanosine, deoxyadenosine, and deoxycytidine from digested genomic DNA. Assay application was demonstrated with genomic DNA digested from multiple murine cell lines treated with ceralasertib. Chromatographic separation was achieved with an Inertsil ODS‐3 (150 × 2.1 mm, 3 μm) column and a gradient elution program of 0.1% formic acid in water and 0.1% formic acid in methanol over an 18‐min run time. Detection was performed on a SCIEX 6500+ tandem mass spectrometer. The method proved to be accurate (90.8%–114.2%) and precise (< 7.73% CV) across analytes. Freeze–thaw stability (106.4%–114.3%), stability for 12 months at −80°C (88.7%–113.7%), and stability for 4 h at room temperature (104.1%–114.0%) were acceptable across QCs.

  • Open Access

    Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival

    by Joshua Deppas, Brian F. Kiesel, Frank P. Vendetti, Pinakin Pandya, Jianxia Guo, Kristine L. Cooper, Matthew J. Bakkenist, Meysam Tavakoli, Maria Dimayorca, Naveed M Islam, et al.

    Background: ATR activation following DNA damage from cancer treatments such as radiation can mitigate anticancer efficacy, making ATR inhibitors (ATRi) an attractive therapeutic. In vivo and in vitro studies have shown enhanced tumor cell radiosensitivity with the ATRi ceralasertib, elimusertib, and berzosertib, however, the potentiating effect of ATRi on ionizing radiation (IR) through immune-based mechanisms has only been studied with ceralasertib. Methods: We aimed to determine if antitumor immune responses observed with ceralasertib in combination with IR extend to the other ATRi class members in the preclinical CT26 mouse model. We also examined the relationship between exposure and immune stimulation, efficacy and survival outcomes of each ATRi when combined with IR. Results: Ceralasertib and elimusertib, not berzosertib, synergized with IR in a dose and schedule-dependent manner to modify tumor antigen-specific CD8 + T cell populations in the draining lymph node. Transient ATRi therapy, combined with IR, enhances antitumor efficacy, promoted tumor shrinkage, and increased survival. ATRi elicited differential inflammatory gene induction and dose-dependent unique cytotoxicity profiles in vitro . Conclusion: The immune mediated antitumor effect of ATRi combined with radiation is dose and schedule dependent, and while likely a class effect, may differ between ATRi compounds.

  • Open Access

    ATR kinase inhibitors induce mitochondrial fission in CD8 + T cells and impair immune memory in vivo

    by Frank P. Vendetti, Carina R. Sclafani, Yunqi Zhang, Pinakin Pandya, Yvonne M. Mowery, Su Hyeong Kim, Rachel L. Cumberland, Satishkumar R. Ganakammal, Thomas P. Conrads, Michael J. Calderon, et al.

    The DNA damage response kinase ATR restrains CDK1 activity during S and G2 phases of the cell cycle, confining CDK1-driven processes to mitosis. ATR kinase inhibitors were originally developed to potentiate chemotherapy-induced DNA damage at stalled replication forks and to disrupt DNA damage-induced cell cycle checkpoints. Recent evidence, however, reveals that these inhibitors also disrupt cell cycle organization in cells that have not sustained any DNA damage. We show that ATR kinase inhibitors potently trigger unscheduled mitochondrial fission, causing loss of mitochondrial mass in actively dividing CD8 + T cells that persists in memory CD8 + T cells. Moreover, ATR inhibition during the peak of CD8 + T cell expansion in a mouse model of LCMV Armstrong infection impairs the formation of immune memory. These findings carry significant clinical implications. ATR kinase inhibitors are currently being evaluated in clinical trials in combination with chemotherapy, radiation, and immune checkpoint inhibitors in patients where anti-tumor immune responses are recognized as a determinant of durable response. Our results identify an unexpected consequence of ATR inhibition that disrupts cellular metabolism with broad implications for both preclinical research and clinical application.

  • Open Access

    Uracil-DNA glycosylase deficiency is associated with repressed tumor cell-intrinsic inflammatory signaling and altered sensitivity to exogenous interferons

    by Frank P. Vendetti, Pinakin Pandya, Carina R. Sclafani, Reyna E. Jones, Daniel Ivanov, Robert W. Sobol, Christopher J. Bakkenist

    2’-deoxyuridine (dU) is a common DNA lesion resulting from cytosine deamination and from dUMP incorporation by DNA polymerases, both of which are prevalent in cancer. The primary mechanism that repairs dU lesions in genomic DNA is base excision repair initiated by Uracil-DNA Glycosylase 1 (UNG1). We generated Ung knockout mouse B16 melanoma cells to investigate the consequences of UNG deficiency in a well-characterized, immunoproficient, syngeneic mouse cancer model. We show that UNG-deficient (ΔUNG) B16 tumors have altered growth kinetics in vivo and that their delayed growth is T-cell dependent. Immune profiling revealed reduced CD8 + T cell infiltration but augmented CD4 + Th1 responses in ΔUNG tumors. In vitro , ΔUNG tumor cells exhibit strongly suppressed cell-intrinsic type-I interferon, type-II interferon, and inflammatory signaling gene expression signatures as well as altered cytokine and chemokine secretion. In vivo , ΔUNG tumors exhibit a modified inflammatory cytokine and chemokine milieu. Furthermore, ΔUNG tumor cells have altered sensitivity to exogenous interferons in vitro , with increased sensitivity to IFN-γ but decreased sensitivity to IFN-α/β. Collectively, our data show that tumor cell-specific UNG deficiency results in an altered tumor microenvironment in vivo and provide proof-of-concept data for the use of UNG inhibitors to modulate inflammatory pathways in tumors.


  • Open Access

    Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapy

    by Pinakin Pandya, Frank P. Vendetti, Joseph El-Ghoubaira, Sudipta Pathak, Joshua J. Deppas, Reyna Jones, Anthony V. Columbus, Yunqi Zhang, Daniel Ivanov, Ziyu Huang, et al.

    DNA damage and cytoplasmic DNA induce type-1 interferon (IFN-1) and potentiate responses to immune checkpoint inhibitors. Our prior work found that inhibitors of the DNA damage response kinase ATR (ATRi) induce IFN-1 and deoxyuridine (dU) incorporation by DNA polymerases, akin to antimetabolites. Whether and how dU incorporation is required for ATRi-induced IFN-1 signaling is not known. Here, we show that ATRi-dependent IFN-1 responses require uracil DNA glycosylase (UNG)-initiated base excision repair and STING. Quantitative analyses of nine distinct nucleosides reveals that ATRi induce dU incorporation more rapidly in UNG wild-type than knockout cells, and that induction of IFN-1 is associated with futile cycles of repair. While ATRi induce similar numbers of micronuclei in UNG wild-type and knockout cells, dU containing micronuclei and cytoplasmic DNA are increased in knockout cells. Surprisingly, DNA fragments containing dU block STING-dependent induction of IFN-1, MHC-1, and PD-L1. Furthermore, UNG knockout sensitizes cells to IFN-γ in vitro , and potentiates responses to anti-PD-L1 in resistant tumors in vivo . These data demonstrate an unexpected and specific role for dU-rich DNA in suppressing STING-dependent IFN-1 responses, and show that UNG-deficient tumors have a heightened response to immune checkpoint inhibitors. STATEMENT OF SIGNIFICANCE: Antimetabolites disrupt nucleotide pools and increase dU incorporation by DNA polymerases. We show that unrepaired dU potentiates responses to checkpoint inhibitors in mouse models of cancer. Patients with low tumor UNG may respond to antimetabolites combined with checkpoint inhibitors, and patients with high tumor UNG may respond to UNG inhibitors combined with checkpoint inhibitors.


  • Open Access

    The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

    by Frank P. Vendetti, Pinakin Pandya, David A. Clump, Sandra Schamus-Haynes, Meysam Tavakoli, Maria Dimayorca, Naveed M. Islam, Jina Chang, Greg M. Delgoffe, Jan H. Beumer, et al.

    Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by chemotherapies that target DNA replication forks but also kill rapidly proliferating immune cells including activated T cells. Nevertheless, ATR inhibitor (ATRi) and radiotherapy (RT) can be combined to generate CD8 + T cell–dependent antitumor responses in mouse models. To determine the optimal schedule of ATRi and RT, we determined the impact of short-course versus prolonged daily treatment with AZD6738 (ATRi) on responses to RT (days 1–2). Short-course ATRi (days 1–3) plus RT caused expansion of tumor antigen–specific, effector CD8 + T cells in the tumor-draining lymph node (DLN) at 1 week after RT. This was preceded by acute decreases in proliferating tumor-infiltrating and peripheral T cells and a rapid proliferative rebound after ATRi cessation, increased inflammatory signaling (IFN-β, chemokines, particularly CXCL10) in tumors, and an accumulation of inflammatory cells in the DLN. In contrast, prolonged ATRi (days 1–9) prevented the expansion of tumor antigen–specific, effector CD8 + T cells in the DLN, and entirely abolished the therapeutic benefit of short-course ATRi with RT and anti–PD-L1. Our data argue that ATRi cessation is essential to allow CD8 + T cell responses to both RT and immune checkpoint inhibitors.


  • Open Access

    Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression

    by Norie Sugitani, Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva, Sandra Schamus-Haynes, Yiyang Wang, Drake Palmer, Hatice U. Osmanbeyoglu, et al.


  • Open Access

    Short-course but not prolonged treatment with ATR inhibitor AZD6738 integrates with radiotherapy to generate a tumor antigen-specific CD8 + T cell expansion in the periphery

    by Frank P. Vendetti, David A. Clump, Sandra Schamus-Haynes, Maria DiMayorca, Naveed Islam, Jina Chang, Jan H. Beumer, Christopher J. Bakkenist

    ATR kinase is a central regulator of the DNA damage response. While ATR kinase inhibitors (ATRi’s) are known to sensitize cancer cells to DNA damage, their effect on immune cells is not known. Here we show in mice that short-course AZD6738 (ATRi) on days 1-3 decreases proliferating T cells in the tumor and periphery and that cessation of ATRi causes a proliferative rebound. Integrating radiation on days 1-2 (RT) with ATRi on days 1-3 increases IFN-β in the tumor and activates tumor antigen-specific CD8 + T cells in the tumor-draining lymph node (DLN). RT with short-course ATRi induces an expansion of tumor antigen-specific CD8 + T cells in the DLN. In contrast, RT with prolonged daily ATRi blocks expansion of antigen-specific CD8 + T cells, despite increased IFN-β and activation of CD8 + T cells. Our data identifies critical schedule considerations for ATRi with RT, immunotherapy and genotoxic therapies.

  • Open Access

    Thymidine rescues ATR kinase inhibition induced deoxyuridine contamination in genomic DNA, cell death, and Type 1 interferon expression

    by Norie Sugitani, Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva, Sandra Schamus-Haynes, Yiyang Wang, Drake Palmer, Hatice U. Osmanbeyoglu, et al.

    SUMMARY: ATR kinase is a central regulator of the DNA damage response (DDR) and cell cycle checkpoints. ATR kinase inhibitors (ATRi’s) combine with radiation to generate CD8 + T cell-dependent responses in mouse models of cancer. We show that ATRi’s induce CDK1-dependent origin firing across active replicons in CD8 + T cells activated ex vivo while simultaneously decreasing the activity of rate-limiting enzymes for nucleotide biosynthesis. These pleiotropic effects of ATRi induce deoxyuridine (dU) contamination in genomic DNA, R loops, RNA-DNA polymerase collisions, and type-1 interferons (IFN-1). Remarkably, thymidine rescues ATRi-induced dU contamination, cell death, and IFN-1 expression in proliferating CD8 + T cells. Thymidine also rescues ATRi-induced cancer cell death. We propose that ATRi-induced dU contamination contributes to dose-limiting leukocytopenia and inflammation in the clinic and CD8 + T cell dependent anti-tumor responses in mouse models. We conclude that ATR is essential to limit dU contamination in genomic DNA and IFN-1 expression.


  • Dormant origin signaling during unperturbed replication

    by Tatiana N. Moiseeva, Christopher J. Bakkenist